The following data is part of a premarket notification filed by Valeant Pharmaceuticals with the FDA for Biafine.
| Device ID | K173549 |
| 510k Number | K173549 |
| Device Name: | BIAFINE |
| Classification | Dressing, Wound, Drug |
| Applicant | Valeant Pharmaceuticals 1400 North Goodman Street Rochester, NY 14609 |
| Contact | Melissa Thomas |
| Correspondent | Marci Halevi Valeant Pharmaceuticals 400 Somerset Corporate Boulevard Bridgewater, NJ 08807 |
| Product Code | FRO |
| CFR Regulation Number | 510(k) Premarket Notification [🔎] |
| Decision | Substantially Equivalent (SESE) |
| Type | Traditional |
| 3rd Party Reviewed | No |
| Combination Product | Yes |
| Date Received | 2017-11-16 |
| Decision Date | 2018-08-13 |
| Summary: | summary |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() BIAFINE 75392423 2270330 Live/Registered |
BAUSCH HEALTH IRELAND LIMITED 1997-11-19 |
![]() BIAFINE 75392423 2270330 Live/Registered |
WENMAEKERS, Michel 1997-11-19 |
![]() BIAFINE 74496392 1923213 Live/Registered |
BAUSCH HEALTH IRELAND LIMITED 1994-03-01 |
![]() BIAFINE 74496392 1923213 Live/Registered |
WENMAEKERS, Michel 1994-03-01 |